



Content highlights

Release date

2023

Updated biannually to reflect Clarivate's expert analysis of the latest major-market events

Geography

United States, EU5, Japan

Primary and secondary research

Extensive secondary research conducted by subject matter experts at Clarivate, supported by extensive primary market research with 550 physicians and 70 payers.

Key brands covered

Actemra / RoActemra, Aranesp, Avastin, Cosentyx, Cyramza, Darzalex, Enbrel, Epogen, Eylea, Gran, Herceptin, Humira, Keytruda, Lantus, Lucentis, Mircera, Neulasta, Neupogen, NovoLog, NovoMix, Opdivo, Perjeta, Remicade, Rituxan / MabThera, Stelara, Taltz, Toujeo, Xolair, Yervoy

Content highlights

Total and individual biosimilar patient shares.

Pricing expectations for biosimilars and brands.

Forecasted biosimilar- and brand-treated patient numbers.

Biosimilars

Spotlight on Biosimilars Forecast

Market outlook

The biosimilars market is set to grow rapidly over the next decade, based on the growing number of biosimilars in development and the increased number of recently approved biosimilars globally. By 2031, biosimilars will have a wide-ranging market share depending on the class of biologic. This expectation highlights the variability in the anticipated uptake of biosimilars across biological classes and indications, as well as differences in market-entry dates. Key drivers of biosimilar uptake in the major markets (United States, EU5, and Japan) under study include the patent expiration of high-selling biologics, continued pressures on healthcare systems to contain healthcare costs and technological advances in biologic analytics and cost-effective manufacturing.

Questions answered

- What is the future market size for biosimilars at a regional level, class and molecule level?
- When will different biosimilars enter the major markets (i.e., United States, EU5, and Japan) and how will they behave?
- How will pricing dynamics evolve between brands and biosimilars throughout the forecast period?
- Which biosimilar marketers are anticipated to win the greatest market share when competing with multiple biosimilars referencing the same brand molecule?
- What is the biosimilar patient share split by biosimilar products, that are expected to launch during the forecast period, also listed by companies marketing these biosimilars (%)
- The total sales of the reference brand following the launch of new biosimilars after the first year of the forecast period. Also, the total biosimilar sales, split by each biosimilar product (in millions of U.S. dollars).
- What are the key strategies employed to drive biosimilar uptake?
- Key companies covered: Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Eli Lilly, Janssen, Merck & Co., Mundipharma, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Sanofi, Teva, Viatris (Mylan).

Product description

Clarivate's *Biosimilars | Forecast* module assesses the current and future market size for biosimilars in six leading therapy areas: oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology. Our forecast insights provide comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, valuable knowledge on the impact of payer policy on biosimilars uptake, and drug forecasts supported by detailed primary and secondary research. View interactive forecasts at the brand level for the United States, Europe and Japan.

Learn more about Clarivate's full suite of biosimilars solutions:

DRG.support@clarivate.com | clarivate.com